Nature Communications (Aug 2016)

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers

  • Christopher A. Miller,
  • Yevgeniy Gindin,
  • Charles Lu,
  • Obi L Griffith,
  • Malachi Griffith,
  • Dong Shen,
  • Jeremy Hoog,
  • Tiandao Li,
  • David E. Larson,
  • Mark Watson,
  • Sherri R Davies,
  • Kelly Hunt,
  • Vera J. Suman,
  • Jacqueline Snider,
  • Thomas Walsh,
  • Graham A. Colditz,
  • Katherine DeSchryver,
  • Richard K. Wilson,
  • Elaine R. Mardis,
  • Matthew J. Ellis

DOI
https://doi.org/10.1038/ncomms12498
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 10

Abstract

Read online

Aromatase inhibitors are used to treat oestrogen-receptor-positive breast cancer. Here, the authors use genomic approaches to analyse tumours before and after neo-adjuvant treatment and find that treatment alters the clonal landscape of the tumours.